- Home
- JAZZ vs ELS Comparison
JAZZ vs ELS Comparison
Compare JAZZ & ELS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | ELS |
|---|---|---|
| Founded | 2003 | 1992 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 11.7B |
| IPO Year | 2007 | 1993 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | ELS |
|---|---|---|
| Price | $168.86 | $63.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | ★ $207.19 | $70.88 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 02-24-2026 | 01-27-2026 |
| Dividend Yield | N/A | ★ 3.32% |
| EPS Growth | N/A | ★ 2.36 |
| EPS | N/A | ★ 1.99 |
| Revenue | ★ $4,157,832,999.00 | $1,535,911,000.00 |
| Revenue This Year | $6.00 | $1.08 |
| Revenue Next Year | $6.35 | $4.39 |
| P/E Ratio | ★ N/A | $31.17 |
| Revenue Growth | ★ 4.14 | 0.93 |
| 52 Week Low | $95.49 | $58.15 |
| 52 Week High | $182.99 | $70.35 |
Technical Indicators
Market Signals| Indicator | JAZZ | ELS |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 65.95 |
| Support Level | $159.35 | $60.25 |
| Resistance Level | $173.09 | $61.71 |
| Average True Range (ATR) | 5.80 | 1.02 |
| MACD | -0.29 | 0.32 |
| Stochastic Oscillator | 65.44 | 97.11 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 455 properties across the US with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.